Search
Memorial Sloan Kettering researchers have discovered how a common bacterium can evolve to become more mobile and easier to get rid of.
Scientists have identified genes and biological mechanisms that one day could be targeted with drugs to stop kidney cancer from spreading to the bone, brain, or other organs.
After an extensive nationwide search, Memorial Sloan Kettering Cancer Center (MSK) announced today that Lisa M. DeAngelis has been named Physician-in-Chief and Chief Medical Officer. A leading expert in brain cancer, Dr. DeAngelis previously served as Chair of the Department of Neurology and was co-founder of MSK’s Brain Tumor Center during her 30-plus-year tenure at the institution.
The 2021 ASCO Annual Meeting will bring together one of the largest, most diverse audiences in oncology and provide engaging broadcast and on-demand presentations of the latest cutting-edge oncology research. ASCO 2021 will focus on Equity: Every Patient. Every Day. Everywhere.
Breakthrough findings were presented at the 2022 ASCO Annual Meeting and published in The New England Journal of Medicine today by researchers at Memorial Sloan Kettering Cancer Center (MSK) confirming a clinical complete response in all 14 patients who received the immunotherapy treatment dostarlimab as a first-line treatment for mismatch repair-deficient (MMRd) locally advanced rectal cancer. This new approach of “immunoablative” therapy uses immunotherapy to replace surgery, chemotherapy and radiation to remove cancer.
Researchers have found that the genetic changes that cause pediatric leukemia are different from those that lead to leukemia in adults.
New MSK research finds a potential therapeutic opportunity in regulatory T cells’ resilience to the loss of Foxp3; shows how cancer develops resistance to antibody-drug conjugates; develops a new system to help make gene editing safer and more reliable; and shows provider billing margin doesn’t drive cancer treatment selection.
The insights lay the groundwork for earlier diagnosis and better treatment of the disease.
Learn about Dr. Kojo Elenitoba-Johnson, who leads teams of Memorial Sloan Kettering experts in interpreting lab tests and diagnosing cancer as the inaugural Chair of the MSK Department of Pathology and Laboratory Medicine. He is also a member in the Human Oncology and Pathogenesis Program.
Memorial Sloan Kettering Cancer Center (MSK) has appointed Tracy Gosselin, PhD, RN, AOCN, NEA-BC, FAAN, as Senior Vice President, Chief Nurse Executive, and Chair of Nursing effective November 2021.